Neulasta® - Proactive Risk Assessment

Neulasta® (pefgilgrastim). Start with support

Proactive

Risk Assessment

Many factors identify patients at risk for febrile neutropenia

Research to date has identified a number of factors that predict a patient’s risk for neutropenic events:^20,21


		Increasing age
		Poor performance status
		Advanced cancer
		Bone marrow involvement
		Comorbid disease
		Active tissue infection
		History of recurrent chemotherapy-induced neutropenia
		Low serum albumin (non-Hodgkin’s lymphoma)
		High lactate dehydrogenase (non-Hodgkin’s lymphoma)
		Preexisting neutropenia: - Prior myelosuppressive therapy - Radiation therapy to bone marrow

A nationwide prospective registry of cancer patients is adding new data on the importance of patient risk factors in assessing the risk of febrile neutropenia.^2,22

In a multivariate analysis, after adjustment for cancer type, age, baseline platelet, neutrophil, and lymphocyte counts, type of chemotherapy (anthracycline based or not), and primary prophylaxis, the following emerged as significant independent predictors of severe or febrile neutropenia in the first cycle of chemotherapy:²²

Examples of significant independent predictors of severe neutropenia or febrile neutropenia in the first cycle²²

Examples of significant independent predictors of severe neutropenia or febrile neutropenia in the first cycle

Odds ratio (95% confidence intervals)

Important: Neulasta^® is indicated in myelosuppressive chemotherapy regimens associated with a febrile neutropenia risk of at least 17%.

See Important Product Safety Information.


	Neulasta^® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Product Safety Information Neulasta^® Prescribing Information \| NEUPOGEN^® (Filgrastim) Prescribing Information \| Medical Information Connection™ \| Site Map \| Amgen.com 2008 Amgen. All rights reserved. This site for use in U.S. only.